FAQ: Quantum BioPharma Ltd. Corporate Update on Debt Settlement, RSU Grants, and Advisor Changes
Summary
What corporate actions did Quantum BioPharma Ltd. announce?
Quantum BioPharma announced the settlement of $26,812.50 in outstanding debt through the issuance of 1,102 Class B shares, granted 800 restricted share units (RSUs) each to clinical advisors Peter Stys and Jack Antel, and confirmed that Kevin Malone is no longer serving as an advisor to the board.
When did these corporate actions take effect?
The debt settlement was approved by the board on August 12, 2025, while the RSU grants and termination of Kevin Malone’s advisory role were effective August 15, 2025.
How are the RSUs granted to clinical advisors structured?
The 800 RSUs each granted to Peter Stys and Jack Antel vest based on regulatory milestones for the company’s Lucid MS program, as part of the equity incentive plan.
What are the trading restrictions on the creditor shares and RSUs?
The creditor shares and RSUs are subject to a four-month-plus-one-day statutory hold under CSE policy and are not registered under the U.S. Securities Act.
Why is the Lucid MS program important to Quantum BioPharma?
Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models, targeting the underlying mechanism of multiple sclerosis, which is central to the company’s neurodegenerative disorder treatments.
What is Quantum BioPharma’s involvement with UNBUZZD™ and Celly Nutrition?
Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to Celly Nutrition Corp., retaining 25.71% ownership as of June 30, 2024, a 7% royalty on sales until $250 million is paid, then 3% in perpetuity, and full rights for pharmaceutical and medical uses. More details are at www.unbuzzd.com.
Where can investors find the latest news and updates about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
What is the focus of Quantum BioPharma’s subsidiary FSD Strategic Investments Inc.?
FSD Strategic Investments Inc., a wholly owned subsidiary of Quantum BioPharma, maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 171898